ArticlePain2009
Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome.
Article in Pain, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Global research states and trends of micro RNA in irritable bowel syndrome: a bibliometric analysis.Clinical and experimental medicine · 2024Pooled it
- Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.Digestion · 2024Guideline
- A Systematic Review of the Effects of Polyols on Gastrointestinal Health and Irritable Bowel Syndrome.Advances in nutrition (Bethesda, Md.) · 2017Pooled it
- Descending pain modulation in irritable bowel syndrome (IBS): a systematic review and meta-analysis.Systematic reviews · 2015Pooled it
- A Randomized, Placebo-Controlled Trial Evaluating Multi-Species Synbiotic Supplementation for Bloating, Gas, and Abdominal Discomfort.Nutrients · 2026Trial
- Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model.Gut microbes · 2025Trial
- Trial
- Effect of a Multistrain Probiotic on Leaky Gut in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study.Digestive diseases (Basel, Switzerland) · 2023Trial
- UCC118 supplementation reduces exercise-induced gastrointestinal permeability and remodels the gut microbiome in healthy humans.Physiological reports · 2019Trial
- Trial
- Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.Gut microbes · 2019Trial
- Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017Trial
- Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease.PloS one · 2016Trial
- Trial
- Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors.The journal of pain · 2012Trial
- Trial
- Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome.The journal of pain · 2011Trial
- Lactiplantibacillus Plantarum CKDB008 and Lacticaseibacillus Rhamnosus LDTM7511 Attenuate Visceral Hypersensitivity and Suppress Serum IgE in an Acetic Acid-Induced IBS-Like Rat Model.Probiotics and antimicrobial proteins · 2026Article
- Effects of Social Pairing on Measurable Disease Outcomes in Hospitalized Rhesus Macaques (Macaca mulatta).American journal of primatology · 2026Article
- Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in which the underlying pathophysiology is poorly understood; however, increased intestinal permeability in diarrhea-predominant IBS patients has been reported. Here we demonstrate that diarrhea-predominant IBS (D-IBS) patients display increased intestinal permeability. We have also found that increased intestinal membrane permeability is associated with visceral and thermal hypersensitivity in this subset of D-IBS patients. We evaluated 54 D-IBS patients and 22 controls for intestinal membrane permeability using the lactulose/mannitol method. All subjects ingested 5g of lactulose and 2g of mannitol in 100ml of water after which their urine was collected. We also evaluated the mean mechanical visual analogue scale (M-VAS) pain rating to nociceptive thermal and visceral stimulation in all subjects. All study participants also completed the FBDSI scale. Approximately 39% of diarrhea-predominant IBS patients had increased intestinal membrane permeability as measured by the lactulose/mannitol ratio. These IBS patients also demonstrated higher M-VAS pain intensity reading scale. Interestingly, the IBS patients with hypersensitivity and increased intestinal permeability had a higher FBDSI score (100.8 + or - 5.4) than IBS patients with normal membrane permeability and sensitivity (51.6 + or - 12.7) and controls (6.1 + or - 5.6) (p<0.001). A subset of D-IBS patients had increased intestinal membrane permeability that was associated with an increased FBDSI score and increased hypersensitivity to visceral and thermal nociceptive pain stimuli. Thus, increased intestinal membrane permeability in D-IBS patients may lead to more severe IBS symptoms and hypersensitivity to somatic and visceral stimuli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.